BerGenBio hopes to get an early indication of its drug bemcentinib’s effectiveness in treating the most vulnerable COVID-19 patients, the company said. The drug was originally designed to interfere with a tumour’s ability to suppress the body’s immune response against it. The company said the trial is part of its participation in the UK’s ACCORD initiative, short for Accelerating COVID-19 Research & Development. Reuters
Wednesday, April 29, 2020
BerGenBio shares soar on COVID-19 drug trial news
BerGenBio hopes to get an early indication of its drug bemcentinib’s effectiveness in treating the most vulnerable COVID-19 patients, the company said. The drug was originally designed to interfere with a tumour’s ability to suppress the body’s immune response against it. The company said the trial is part of its participation in the UK’s ACCORD initiative, short for Accelerating COVID-19 Research & Development. Reuters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment